EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY

Equipe constitutive du CERPOP, UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier
Émilie JOUANJUS •  chercheure


2023
  1. Aquizerate A, Laforgue EJ, Istvan M, Rousselet M, Gerardin M, Jouanjus E, Libert F; French Addictovigilance Network; Guerlais M, Victorri-Vigneau C. French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change. Eur J Public Health. 2023 Apr 1;33(2):169-175. doi: 10.1093/eurpub/ckad003.
     
  2. Diaz L, Eiden C, Jouanjus E, Frauger E, Fouilhé N, Djezzar S, Gibaja V, Boucher A, Le Boisselier R, Libert F, Caous AS, Monzon E, Guerlais M, Daveluy A, Fauconneau B, Peyrière H. Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020. Therapie. 2023 Feb 15:S0040-5957(23)00030-6. doi: 10.1016/j.therap.2023.02.002. Epub ahead of print.
     
  3. Robert M, Jouanjus E, Khouri C, Fouilhé Sam-Laï N, Revol B. The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database. Addiction. 2023 Apr;118(4):771-775. doi: 10.1111/add.16081.
2022
  1. Belančić A, Sans-Pola C, Jouanjus E, Alcubilla P, Arellano AL, Žunić M, Nogueiras-Álvarez R, Roncato R, Sáez-Peñataro J; EACPT Young Clinical Pharmacologists Working Group. European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology. Eur J Clin Pharmacol. 2022 Apr;78(4):691-694. doi: 10.1007/s00228-022-03277-3.
     
  2. Jouanjus E, Gibaja V, Fabre F, Lapeyre-Mestre M; OSIAP Working Group on opioid cough suppressants. Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France. Br J Clin Pharmacol. 2022 Apr;88(4):1713-1721. doi: 10.1111/bcp.15052.
     
  3. Roussin A, Soeiro T, Fouque C, Jouanjus E, Frauger E, Fouilhé N, Mallaret M, Micallef J, Lapeyre-Mestre M; French Addictovigilance Network (FAN). Increase of high-risk tramadol use and harmful consequences in France from 2013-2018: evidence from the triangulation of addictovigilance data. Br J Clin Pharmacol. 2022 Mar 22. doi: 10.1111/bcp.15323. Epub ahead of print.
     
  4. Revol B, Lapeyre-Mestre M, Fouilhé Sam-Laï N, Jouanjus E. Association between NMDAR antagonists, drug abuse and dependence: A disproportionality analysis from the WHO pharmacovigilance database. Br J Clin Pharmacol. 2022 Nov;88(11):4937-4940. doi: 10.1111/bcp.15430.
2021
  1. Bouquet E, Pain S, Eiden C, Jouanjus E, Richard N, Fauconneau B, Pérault-Pochat MC; French Addictovigilance Network. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012-2017). Br J Clin Pharmacol. 2021 Oct;87(10):3925-3937. doi: 10.1111/bcp.14812.
     
  2. Herin F, Othenin J, Jouanjus E, Rousseau V, Niezborala M, Lapeyre-Mestre M. Evolution of medication consumption in a working environment in France: Results of the four waves of the "Drugs and Work" study (1986-2016). Pharmacoepidemiol Drug Saf. 2021 May;30(5):661-668. . doi: 10.1002/pds.5211.
     
  3. Jobert A, Laforgue EJ, Grall-Bronnec M, Rousselet M, Péré M, Jolliet P; FAN-Network, Feuillet F, Victorri-Vigneau C, (Jouanjus E collaborator). Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Eur J Clin Pharmacol. 2021 Feb;77(2):171-177. doi: 10.1007/s00228-020-03007-7.
     
  4. Jouanjus E, Gibaja V, Fabre F, Lapeyre-Mestre M; OSIAP Working Group. Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from OTC to prescription-only in France. Br J Clin Pharmacol. 2021 Aug 24. doi: 10.1111/bcp.15052. Epub ahead of print.
     
  5. Jouanjus E, Sans-Pola C, Mainoli B, Javid FA, Ekheden I; Working Group on Medical Cannabis Projects of the EACPT Young Clinical Pharmacologists. Establishing and Evaluating a Study Questionnaire on Knowledge and Attitudes of Healthcare Professionals Towards Recreational and Medical Cannabis Across Europe. Clin Drug Investig. 2021 Aug;41(8):701-710. doi: 10.1007/s40261-021-01058-x.
     
  6. Revol B, Delorme J, Jouanjus É, Spadari M, Djezzar S, Lepelley M, Khouri C, Fouilhé Sam-Laï N, Mallaret M; le réseau français des Centres d’addictovigilance. Thirty years of nefopam abuse in France. Therapie. 2021 Nov-Dec;76(6):527-537. French. doi: 10.1016/j.therap.2021.01.058.
     
  7. Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M; French Addictovigilance Network (FAN). Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance. Front Psychiatry. 2021 Feb 3;12:639780. doi: 10.3389/fpsyt.2021.639780.
2020
  1. Jobert A, Laforgue EJ, Grall-Bronnec M, Rousselet M, Péré M, Jolliet P; FAN-Network (Jouanjus E collaborator), Feuillet F, Victorri-Vigneau C. Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Eur J Clin Pharmacol. 2021 Feb;77(2):171-177. doi: 10.1007/s00228-020-03007-7.
     
  2. Jouanjus E, Wolff V. Cerebrovascular disease in the context of cannabis. La Presse Médicale. 2020;4:364-372. doi : 10.1016/j.lpmfor.2020.07.013 
     
  3. Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, Peyrière H, Micallef J; French Addictovigilance Network. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020 Jul-Aug;75(4):343-354. doi: 10.1016/j.therap.2020.06.006.
  4. Lapeyre-Mestre M, Jouanjus E. Cardiovascular disorders attributed to cannabis. La Presse Médicale. 2020;4:355-363. doi: 10.1016/j.lpmfor.2020.08.009.
     
  5. Mongiatti M, Bayle P, Lagarrigue A, Fabre D, Telmon N, Lapeyre-Mestre M, Jouanjus E. The cardiovascular health of prisoners who use cannabis: An exploratory study among hospitalised prisoners. Therapie. 2020 Nov-Dec;75(6):579-589. doi: 10.1016/j.therap.2020.06.017.
2019
  1. Auffret M, Rolland B, Béhal H, Labreuche J, Jouanjus E, Bordet R, Gautier S. A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France. Therapie. 2019 Dec;74(6):645-650. doi: 10.1016/j.therap.2019.06.002.
     
  2. Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, Guiard BP, Jouanjus E. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology (Berl). 2019 Jul;236(7):2069-2082. doi: 10.1007/s00213-019-05198-z.
     
  3. Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019 Jun;85(6):1260-1269. doi: 10.1111/bcp.13892.
     
  4. Jouanjus E, Lapeyre-Mestre M, Nodot M, Roussin A, Franchitto N, Boyes JP, Nasr N, Oustric S, Dupouy J. Teaching Basic Knowledge on Substance Use Disorders: The Impact of e-Learning on Health Professionals. Clin Ther. 2019 Oct;41(10):2154-2161. doi: 10.1016/j.clinthera.2019.07.012.
     
  5. Jouanjus E, Micallef J, Mallaret M, Lapeyre-Mestre M. Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019 Aug 1;22(8):528-530. doi: 10.1093/ijnp/pyz033.
     
  6. Micallef J, Jouanjus E, Mallaret M, Lapeyre Mestre M. Détection des signaux du réseau français d’addictovigilance : méthodes innovantes d’investigation, illustrations et utilité pour la santé publique [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health]. Therapie. 2019 Dec;74(6):579-590. French. doi: 10.1016/j.therap.2019.09.005.